IC
FTH

Ikarian Capital’s Faeth Therapeutics FTH Stock Holding History

Ikarian Capital’s Portfolio FTH Stock Details FTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$885K Buy
35,386
+29,035
+457% +$672K 0.1% 109
2026
Q1 		$200K Sell
6,351
-15,000
-70% -$300K 0.02% 141
2025
Q4 		$228K Sell
21,351
-1,146
-5% -$11.1K 0.02% 151
2025
Q3 		$213K Hold
22,497
– – 0.02% 151
2025
Q2 		$193K Sell
22,497
-1
-0% -$7 0.04% 113
2025
Q1 		$177K Sell
22,498
-10,000
-31% -$95.1K 0.02% 142
2024
Q4 		$319K Sell
32,498
-2
-0% -$20 0.04% 140
2024
Q3 		$389K Hold
32,500
– – 0.05% 121
2024
Q2 		$403K Buy
+32,500
New +$676K 0.07% 98

Other funds holding FTH

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
BGI
B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return

Ikarian Capital's FTH Position: Q2 2026 in Review

Ikarian Capital increased its Faeth Therapeutics (FTH) stake by 457% in Q2 2026, buying an estimated $672K and bringing the position to 35,386 shares worth $885K. The position accounts for 0.1% of the portfolio, ranked #109.

Ikarian Capital first reported a position in FTH in Q2 2024 and has held it in 9 quarters since. 45 funds tracked by Wall St. Rank hold FTH as of Q2 2026.

  • Ikarian Capital held 35,386 shares of Faeth Therapeutics worth $885K as of Q2 2026.
  • Ikarian Capital bought 29,035 Faeth Therapeutics shares in Q2 2026, an estimated $672K.
  • Faeth Therapeutics made up 0.1% of Ikarian Capital's portfolio in Q2 2026, its #109 holding.
  • Ikarian Capital first reported a position in Faeth Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • 45 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.